Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)

NCT06007677 is registered in ClinicalTrials.gov with Astria Therapeutics, Inc. as lead sponsor.

NCT NCT06007677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)
Lead sponsor
Astria Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 26, 2023
Completion date
March 31, 2031
Enrollment
56 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema